Skip to main content
. 2017 Nov 24;8(65):109151–109160. doi: 10.18632/oncotarget.22642

Figure 4. CD122 mAb treatment of B16-OVA tumors increased the frequency and function of specific inflammatory cytokine production of tumor infiltrating T cells and efficacy is dependent on CD8+ T cells.

Figure 4

(A) Summary data showing percentage of CD4+CD45+ TILs expressing IFNγ. (B-C) Representative and summary data showing single-, double- and triple positive CD8+ T cells releasing IFNγ, TNFα and/or co-expressing the degranulation marker, CD107a, following OVA257-264 and OVA323-339 peptide incubation with PMA/ION stimulation. (D) Tumor growth curves and survival over time for B16-OVA tumor-bearing mice treated aCD122 and with/without anti-CD4 or anti-CD8 mAbs. Experiments were repeated at least two times. *P<0.05; **P<0.01; ***P<0.001. Errors bars indicate SEM of n = 5/group (A-C); n= 10/group in (D).